Stock Events

Stock Events

Atara Biotherapeutics 

0
95
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10AugExpected
Q1 2026
Next
-0.28
-0.27
-0.26
-0.25
Expected EPS
-0.27625500000000003
Actual EPS
N/A

Financials

27.83%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
109.93MRevenue
30.59MNet Income

Analyst Ratings

8.73Average Price Target
The highest estimate is 9.86.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AT2.MU. It's not an investment recommendation.
Amazon
17
AMZN
Microsoft
16
MSFT
Apple
14
AAPL
NVIDIA
14
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Allogene Therapeutics
ALLO
Mkt Cap690.31M
Allogene Therapeutics is involved in the development of allogeneic CAR-T therapies, directly competing with Atara's allogeneic T-cell immunotherapy approach.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the CAR-T and T-cell receptor (TCR) therapy space, similar to Atara's focus areas.
Novartis
NVS
Mkt Cap293.94B
Novartis is a major player in the CAR-T therapy market with Kymriah, competing in the same space as Atara's T-cell immunotherapy products.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has investments in CAR-T and other immunotherapies, positioning it as a competitor in the broader immunotherapy market.
AMGEN
AMGN
Mkt Cap196.12B
Amgen's focus on innovative therapies and investments in immuno-oncology position it as a competitor in the immunotherapy and cell therapy markets.

About

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Show more...
CEO
Dr. Pascal Touchon D.V.M.
Employees
173
Country
United States
ISIN
US0465131078

Listings

MU
DE
AT2.MU
STU
DE
AT20.STU
F
DE
AT20.F
XNAS
US
ATRA

0 Comments

Share your thoughts

FAQ

What is Atara Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Atara Biotherapeutics stocks are traded under the ticker AT2.MU.
When is the next Atara Biotherapeutics earnings date?▼
Atara Biotherapeutics is going to release the next earnings report on August 10, 2026.
What were Atara Biotherapeutics earnings last quarter?▼
AT2.MU earnings for the last quarter are -0.25 EUR per share, whereas the estimation was -0.28 EUR resulting in a +12% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Atara Biotherapeutics revenue for the last year?▼
Atara Biotherapeutics revenue for the last year amounts to 109.93M EUR.
What is Atara Biotherapeutics net income for the last year?▼
AT2.MU net income for the last year is 30.59M EUR.
How many employees does Atara Biotherapeutics have?▼
As of July 22, 2026, the company has 173 employees.
In which sector is Atara Biotherapeutics located?▼
Atara Biotherapeutics operates in the Health & Wellness sector.
When did Atara Biotherapeutics complete a stock split?▼
The last stock split for Atara Biotherapeutics was on June 20, 2024 with a ratio of 1:25.
Where is Atara Biotherapeutics headquartered?▼
Atara Biotherapeutics is headquartered in Thousand Oaks, United States.